Vast Potential for Clinical Trial Opportunities; Adipose Tissue Derived Mesenchymal Stem Cells
J Indian Med Assoc
;
2022 Apr; 120(4): 32-37
Artigo
| IMSEAR
| ID: sea-216530
ABSTRACT
Introduction:
This is a research innovation that aims to provide an additional therapeutic tool. It will open up a vast panorama of regenerative medicine by application of Adipose Derived Mesenchymal Stem Cells (ADMSCs). ADMSCs are selected since a large amount is available for lipoaspiration and a larger percentage (30%) of Mesenchymal Stem Cells (MSCs) obtainable there from. The applications in clinical practice extend across Mesoderm, Endoderm and Ectoderm layers1. Material andMethods:
There are three products that can be derived from the lipoaspirate. They are (1) Stromal Vascular Fraction (SVF), (2) Islet Cell Aggregates (ICAs) Translated from ADMSCs, (3) and ADMSCs with ~95% purity. They are deployed to illustrate the safety and efficacy in clinical trials for (1) Mesoderm Translation as in Osteoarthritis Knee, (2) Endoderm translation to Insulin-producing Cells as applicable to diabetes, and (3) Ectodermal Translation as applicable on Non-healing Indolent Ulcers on the Skin.Results:
All three products are found safe with no adverse side effects. Proof of concept studies along with initial clinical trials for Osteoarthritis, Diabetes Types I and II, and Non-healing ulcer of any aetiology is demonstrated with objective evidence.Discussion:
The evidence based on the results of the clinical trials across all three Germinal Layers is cited along with literature support. Results are explained based on a plausible scientific hypothesis.Conclusion:
The study enunciates that Autologous SVF and ADMSCs are in futuristic domain for conducting clinical trials across all the three Germinal Layers.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Revista:
J Indian Med Assoc
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS